drugset
drugset / Trial / NCT05103423

Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT05103423 ↗

Phase 1/2 Completed 50 enrolled Staidson (Beijing) Biopharmaceuticals Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A study to explore the safety and efficacy of treatment with BDB-001 Injection in adults with moderate to severe hidradenitis suppurativa (HS).

Timeline

Start
2021-06-24
Primary completion
2023-07-07
Completion
2023-07-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Resiquimod Small molecule — Intravenous

Indications

hidradenitis suppurativa